Ozempic Weight Loss Breakthroughs: Real Results From Latest Clinical Studies
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Ozempic Weight Loss Breakthroughs: Real Results From Latest Clinical Studies
-
Narrated by:
-
By:
About this listen
Recent studies highlight impressive results with Ozempic's active ingredient semaglutide. In a 68-week trial detailed by Noom, participants lost an average of 15 percent of their body weight, equaling about 37.5 pounds for a 250-pound person. Meanwhile, Noom reports Zepbound with tirzepatide achieved 21 percent loss in 72 weeks, around 52.5 pounds for the same weight, thanks to targeting both GLP-1 and GIP hormones.
A groundbreaking March 2026 study from Ivim Health in Obesity Pillars shows even better outcomes with comprehensive care. Patients on semaglutide-based therapy lost 21.8 percent at 68 weeks, while tirzepatide users hit 26.54 percent at 72 weeks, with over 99 percent seeing meaningful results. Doctor Jessica Duncan notes intensive oversight, personalized dosing, and lifestyle support drive these superior numbers.
What about stopping? Cleveland Clinic's new analysis of nearly 8,000 patients, published in Diabetes, Obesity and Metabolism, reveals minimal regain. Obesity patients lost 8.4 percent before quitting and regained just 0.5 percent a year later, as many restarted or switched treatments. Doctor Hamlet Gasoyan says real-world switches to alternatives explain less regain than trials.
Encouraging news from Scripps Health in Obesity journal: A study of 30 patients found most maintained 17 percent loss on reduced dosing, like every two weeks after plateau, with stable blood sugar and cholesterol.
Noom emphasizes pairing Ozempic with diet and exercise boosts results, preventing muscle loss or Ozempic face through protein and strength training. Ozempic pens face ongoing shortages per Medfinder, though improved in 2026.
Always consult your doctor, as side effects like nausea occur, and off-label use for weight loss differs from diabetes approval.
Thank you listeners for tuning in. Subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.